1
|
Coukos G, Tanyi J and Kandalaft LE:
Opportunities in immunotherapy of ovarian cancer. Ann Oncol. 27
(Suppl 1):i11–i15. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Smith RA, Andrews KS, Brooks D, Fedewa SA,
Manassaram-Baptiste D, Saslow D, Brawley OW and Wender RC: Cancer
screening in the United States, 2017: A review of current American
Cancer Society guidelines and current issues in cancer screening.
CA Cancer J Clin. 67:100–121. 2017. View Article : Google Scholar : PubMed/NCBI
|
3
|
US Preventive Services Task Force, ;
Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA,
Epling JW Jr, Kemper AR, Krist AH, et al: Screening for ovarian
cancer: US preventive services task force recommendation statement.
JAMA. 319:588–594. 2018. View Article : Google Scholar : PubMed/NCBI
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
5
|
Corrado G, Salutari V, Palluzzi E,
Distefano MG, Scambia G and Ferrandina G: Optimizing treatment in
recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther.
17:1147–1158. 2017. View Article : Google Scholar : PubMed/NCBI
|
6
|
Bristow RE and Chi DS: Platinum-based
neoadjuvant chemotherapy and interval surgical cytoreduction for
advanced ovarian cancer: A meta-analysis. Gynecol Oncol.
103:1070–1076. 2006. View Article : Google Scholar : PubMed/NCBI
|
7
|
Derynck R and Weinberg RA: EMT and cancer:
More than meets the eye. Dev Cell. 49:313–316. 2019. View Article : Google Scholar : PubMed/NCBI
|
8
|
Feng W, Dean DC, Hornicek FJ, Shi H and
Duan Z: Exosomes promote pre-metastatic niche formation in ovarian
cancer. Mol Cancer. 18:1242019. View Article : Google Scholar : PubMed/NCBI
|
9
|
Javan Maasomi Z, Pilehvar Soltanahmadi Y,
Dadashpour M, Alipour S, Abolhasani S and Zarghami N: Synergistic
anticancer effects of silibinin and chrysin in T47D breast cancer
cells. Asian Pac J Cancer Prev. 18:1283–1287. 2017.PubMed/NCBI
|
10
|
Sandilands A, Smith FJ, Lunny DP, Campbell
LE, Davidson KM, MacCallum SF, Corden LD, Christie L, Fleming S,
Lane EB and McLean WH: Generation and characterisation of keratin 7
(K7) knockout mice. PLoS One. 8:e644042013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Woods RSR, Keegan H, White C, Tewari P,
Toner M, Kennedy S, O'Regan EM, Martin CM, Timon CVI and O'Leary
JJ: Cytokeratin 7 in oropharyngeal squamous cell carcinoma: A
junctional biomarker for human papillomavirus-related tumors.
Cancer Epidemiol Biomarkers Prev. 26:702–710. 2017. View Article : Google Scholar : PubMed/NCBI
|
12
|
Hosoya A, Kwak S, Kim EJ, Lunny DP, Lane
EB, Cho SW and Jung HS: Immunohistochemical localization of
cytokeratins in the junctional region of ectoderm and endoderm.
Anat Rec (Hoboken). 293:1864–1872. 2010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Karantza V: Keratins in health and cancer:
More than mere epithelial cell markers. Oncogene. 30:127–138. 2011.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Oue N, Noguchi T, Anami K, Kitano S,
Sakamoto N, Sentani K, Uraoka N, Aoyagi K, Yoshida T, Sasaki H and
Yasui W: Cytokeratin 7 is a predictive marker for survival in
patients with esophageal squamous cell carcinoma. Ann Surg Oncol.
19:1902–1910. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Harbaum L, Pollheimer MJ, Kornprat P,
Lindtner RA, Schlemmer A, Rehak P and Langner C: Keratin 7
expression in colorectal cancer-freak of nature or significant
finding? Histopathology. 59:225–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Lambaudie E, Chereau E, Pouget N,
Thomassin J, Minsat M, Charafe-Jauffret E, Jacquemier J and
Houvenaeghel G: Cytokeratin 7 as a predictive factor for response
to concommitant radiochemotherapy for locally advanced cervical
cancer: A preliminary study. Anticancer Res. 34:177–181.
2014.PubMed/NCBI
|
17
|
Kuroda H, Imai Y, Yamagishi H, Ueda Y,
Kuroso K, Oishi Y, Ohashi H, Yamashita A, Yashiro Y and Fukushima
H: Aberrant keratin 7 and 20 expression in triple-negative
carcinoma of the breast. Ann Diagn Pathol. 20:36–39. 2016.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Wang P, Magdolen V, Seidl C, Dorn J,
Drecoll E, Kotzsch M, Yang F, Schmitt M, Schilling O, Rockstroh A,
et al: Kallikrein-related peptidases 4, 5, 6 and 7 regulate
tumour-associated factors in serous ovarian cancer. Br J Cancer.
119:1–9. 2018. View Article : Google Scholar : PubMed/NCBI
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Chandrashekar DS, Bashel B, Balasubramanya
SA, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BV and Varambally
S: UALCAN: A portal for facilitating tumor subgroup gene expression
and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
|
22
|
Zhou Y, Zhou B, Pache L, Chang M,
Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape
provides a biologist-oriented resource for the analysis of
systems-level datasets. Nat Commun. 10:15232019. View Article : Google Scholar : PubMed/NCBI
|
23
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
|
24
|
Kai F, Drain AP and Weaver VM: The
extracellular matrix modulates the metastatic journey. Dev Cell.
49:332–346. 2019. View Article : Google Scholar : PubMed/NCBI
|
25
|
Cantelli G, Orgaz JL, Rodriguez-Hernandez
I, Karagiannis P, Maiques O, Matias-Guiu X, Nestle FO, Marti RM,
Karagiannis SN and Sanz-Moreno V: TGF-β-induced transcription
sustains amoeboid melanoma migration and dissemination. Curr Biol.
25:2899–2914. 2015. View Article : Google Scholar : PubMed/NCBI
|
26
|
Huang B, Song JH, Cheng Y, Abraham JM,
Ibrahim S, Sun Z, Ke X and Meltzer SJ: Long non-coding antisense
RNA KRT7-AS-as is activated in gastric cancers and supports cancer
cell progression by increasing krt7 expression. Oncogene.
35:4927–4936. 2016. View Article : Google Scholar : PubMed/NCBI
|
27
|
Tajima Y, Ito K, Umino A, Wilkinson AC,
Nakauchi H and Yamazaki S: Continuous cell supply from
Krt7-expressing hematopoietic stem cells during native
hematopoiesis revealed by targeted in vivo gene transfer method.
Sci Rep. 7:406842017. View Article : Google Scholar : PubMed/NCBI
|
28
|
Lu P, Weaver VM and Werb Z: The
extracellular matrix: A dynamic niche in cancer progression. J Cell
Biol. 196:395–406. 2012. View Article : Google Scholar : PubMed/NCBI
|
29
|
Filipe EC, Chitty JL and Cox TR: Charting
the unexplored extracellular matrix in cancer. Int J Exp Pathol.
99:58–76. 2018. View Article : Google Scholar : PubMed/NCBI
|
30
|
Alexander J and Cukierman E: Stromal
dynamic reciprocity in cancer: Intricacies of fibroblastic-ECM
interactions. Curr Opin Cell Biol. 42:80–93. 2016. View Article : Google Scholar : PubMed/NCBI
|
31
|
Byron A, Humphries JD and Humphries MJ:
Defining the extracellular matrix using proteomics. Int J Exp
Pathol. 94:75–92. 2013. View Article : Google Scholar : PubMed/NCBI
|
32
|
Pickup MW, Mouw JK and Weaver VM: The
extracellular matrix modulates the hallmarks of cancer. EMBO Rep.
15:1243–1253. 2014. View Article : Google Scholar : PubMed/NCBI
|
33
|
Piwko-Czuchra A, Koegel H, Meyer H, Bauer
M, Werner S, Brakebusch C and Fässler R: Beta1 integrin-mediated
adhesion signalling is essential for epidermal progenitor cell
expansion. PLoS One. 4:e54882009. View Article : Google Scholar : PubMed/NCBI
|
34
|
Khan Z and Marshall JF: The role of
integrins in TGFβ activation in the tumour stroma. Cell Tissue Res.
365:657–673. 2016. View Article : Google Scholar : PubMed/NCBI
|
35
|
Golubovskaya V: Targeting FAK in human
cancer: From finding to first clinical trials. Front Biosci
(Landmark Ed). 19:687–706. 2014. View
Article : Google Scholar : PubMed/NCBI
|
36
|
Peixoto P, Etcheverry A, Aubry M, Missey
A, Lachat C, Perrard J, Hendrick E, Delage-Mourroux R, Mosser J,
Borg C, et al: EMT is associated with an epigenetic signature of
ECM remodeling genes. Cell Death Dis. 10:2052019. View Article : Google Scholar : PubMed/NCBI
|
37
|
Cicchini C, Laudadio I, Citarella F,
Corazzari M, Steindler C, Conigliaro A, Fantoni A, Amicone L and
Tripodi M: TGFbeta-induced EMT requires focal adhesion kinase (FAK)
signaling. Exp Cell Res. 314:143–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
38
|
Attisano L and Wrana JL: Signal
transduction by the TGF-beta superfamily. Science. 296:1646–1647.
2002. View Article : Google Scholar : PubMed/NCBI
|
39
|
Pardali E, Goumans MJ and Ten Dijke P:
Signaling by members of the TGF-beta family in vascular
morphogenesis and disease. Trends Cell Biol. 20:556–567. 2010.
View Article : Google Scholar : PubMed/NCBI
|
40
|
Zavadil J and Böttinger EP: TGF-beta and
epithelial-to-mesenchymal transitions. Oncogene. 24:5764–5774.
2005. View Article : Google Scholar : PubMed/NCBI
|
41
|
Hajra KM, Chen DY and Fearon ER: The SLUG
zinc-finger protein represses E-cadherin in breast cancer. Cancer
Res. 62:1613–1618. 2002.PubMed/NCBI
|